Andre Goy, MD, John Theurer Cancer Center, Hackensack, NJ, discusses the results of MK-0482-001 (NCT03918278), a Phase I first-in-human study of anti–ILT3 monoclonal antibody MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors presented at the American Society of Clinical Oncology Meeting 2022. 75 who had been heavily pretreated were enrolled. There was no activity observed with MK-0482 as a single agent, however, an overall-response rate (ORR) of 15% was demonstrated in patients who received the combination of MK-0482 plus pembrolizumab. Overall, the combination was well-tolerated, providing moderate activity in patients with heavily pretreated advanced solid tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
